(Beijing / Geneva Comprehensive News) After the control measures of the crown disease epidemic in mainland China, the tide of drug grabbing appeared in many places.Two imitation crown oral medications also flowed into the Chinese market by purchasing, and there were hot sales and out stock.
According to interface news reports, Paxlovid and Molnupiravir developed by Pfizer and Merhadon, respectively.A purchaser on behalf of an overseas pharmaceutical company revealed that the PAXLOVID generic drug it sold for Indian pharmaceutical company Azista was produced. The domestic spot was 1,200 yuan per box (RMB, the same below, 232 yuan).Essence
Although the imitation is authorized by the original pharmaceutical factory, it has not been approved by China.
Many buyers pointed out that PaxLovid has been out of stock in China, and even the goods at the end of December have been sold. The public to buy medicines must wait for the new batch of goods next month.Some buyers also require the buyer to provide the real name of the recipients and the local postal code.
Monabelavavir in Murisha also has similar sales channels in China.According to the buyer, Monabeville was produced by the Laos Pharmaceutical Factory, with a box of 400 yuan per box. The purchase requirements are the same as the PAXLOVID, but the booking time is short. It is estimated that it can be collected in three to five days.
Although the two manufacturers with generic drugs have obtained the license of the original pharmaceutical factory, they have not been approved permits in China, and drug trading is unsatisfactory.Experts also reminded that crown disease oral drugs are prescription medicines and should be used under the conditions of a doctor.
China State Drug Administration approved the import registration of Paxlovid on February 12 this year with emergency review and approval, becoming the first imported crown disease for imported crown disease in China, and Monibilavir has also submitted salesApplication, but not yet approved.
